Beta Bionics (NASDAQ:BBNX) Earns Buy Rating from Analysts at UBS Group

UBS Group assumed coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $22.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the company. Leerink Partners lowered their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Wednesday, April 22nd. The Goldman Sachs Group lifted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Truist Financial increased their target price on Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beta Bionics in a research note on Friday, July 17th. Finally, Stifel Nicolaus lowered their price objective on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus target price of $20.10.

Beta Bionics Stock Down 5.9%

Shares of NASDAQ:BBNX opened at $14.27 on Tuesday. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm’s 50-day simple moving average is $14.97 and its 200-day simple moving average is $13.22. The company has a market cap of $635.87 million, a price-to-earnings ratio of -8.65 and a beta of 3.04.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 25.65% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter. On average, research analysts forecast that Beta Bionics will post -2.22 EPS for the current year.

Insiders Place Their Bets

In other news, insider Mark Hopman sold 5,329 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $67,198.69. Following the sale, the insider owned 130,887 shares in the company, valued at approximately $1,650,485.07. This represents a 3.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Jon Russell sold 4,222 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $53,239.42. Following the transaction, the insider directly owned 173,849 shares in the company, valued at $2,192,235.89. The trade was a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 40,351 shares of company stock valued at $553,961. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently bought and sold shares of BBNX. Eventide Asset Management LLC raised its stake in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after buying an additional 37,476 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in shares of Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after acquiring an additional 424,817 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after acquiring an additional 1,509,217 shares during the last quarter. Eversept Partners LP raised its position in shares of Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Beta Bionics during the 4th quarter valued at approximately $40,437,000.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics reported second-quarter revenue of $32.01 million and an adjusted loss of $0.53 per share, outperforming the consensus loss estimate of $0.62 per share. Beta Bionics Q2 earnings report
• Positive Sentiment: Management raised its full-year 2026 gross-margin outlook to 58.5%-59.5%, a potentially favorable signal for profitability as the company scales its diabetes-management products. Beta Bionics Mint launch and gross-margin outlook
• Positive Sentiment: The company said it expects to launch its Mint product by the end of the second quarter of 2027, providing a potential future growth catalyst. Mint launch announcement
• Neutral Sentiment: Beta Bionics guided to 2026 revenue of $131 million-$136 million, broadly in line with the $133.6 million analyst consensus, limiting the upside surprise from its outlook. Beta Bionics second-quarter results and guidance
• Neutral Sentiment: UBS began research coverage of BBNX, potentially expanding institutional awareness, although the available report does not state a rating or price target. UBS coverage of Beta Bionics
• Negative Sentiment: The quarterly loss widened from $0.39 per share a year earlier to $0.53, while the company remains unprofitable. Investors may also be focused on growth trends and new-patient starts rather than the earnings beat alone.
• Negative Sentiment: Johnson Fistel announced an investigation into potential securities-law violations involving statements or disclosures about Beta Bionics’ growth, new patient starts, business outlook and operating metrics. The announcement does not establish wrongdoing, but it adds legal and reputational risk. Beta Bionics investor investigation alert

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.